{"filings":[{"id":442969,"accession_number":"0001493152-26-023095","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-05-14T20:15:44+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.","Adjusted EBITDA $1.6M (17% margin) vs $0.8M Pro Forma in prior year; operating income margin improved to 12% from 6% Pro Forma.","Thyroid test volume increased 10% YoY; revenue per test up 3%; active accounts increased 5%.","Gross margin expanded to 65% from 59% Pro Forma; company debt-free with $8.7M cash collections in Q1.","Reaffirmed 2026 guidance of ~16% year-over-year thyroid revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":9032000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90946,"accession_number":"0001493152-26-014654","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q4 revenue $9.2M, thyroid revenue +14% YoY; debt fully paid off","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $9.2M, FY revenue $38.7M; Q4 income from cont. ops $22.8M (includes one-time tax adjustment).","Thyroid revenue +14% YoY in Q4, +21% for FY; thyroid volume +11% Q4, +13% FY.","Debt fully paid off in Q4 2025; cash availability up $4.3M YoY.","Adjusted EBITDA Q4 $1.7M, FY $5.4M; company reiterates ~16% thyroid revenue growth guidance for 2026.","Business metrics improved: avg revenue/test +5%, DSO -19%, turnaround time -20%, accounts +9%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":9032000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100808,"accession_number":"0001493152-26-002772","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2026-01-20T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Guidance, and Preferred Stock Conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary 2025 thyroid testing revenue of ~$34-35M, up 21% over prior year.","Company initiates 2026 revenue guidance of ~$40M, representing 16% growth in thyroid testing.","All outstanding Series C Preferred Stock converted into common stock at $2.02 per share, issuing ~23.3M shares.","Company is debt-free with positive net income and EBITDA, plans to seek uplisting to Nasdaq in 2026.","Following conversion, pro forma basic shares outstanding ~27.7M; 1315 Capital owns ~34%, Ampersand owns ~50%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117111,"accession_number":"0001493152-25-025960","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Interpace Biosciences fully repays BroadOak term loan early, strengthens balance sheet","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fully repaid outstanding term loan facility with BroadOak Capital Partners prior to maturity.","Original Loan and Security Agreement dated October 29, 2021 with BroadOak Fund V, L.P.","Early repayment eliminates related interest expenses, increasing operational flexibility.","CFO Chris McCarthy says repayment reflects robust financial performance and disciplined capital management.","Company now focused on driving commercial growth and record testing volumes/revenue for thyroid tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117110,"accession_number":"0001493152-25-021980","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Reports Q3 2025 Revenue of $8.8M, Thyroid Test Volume Up 12% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $8.8M, up 22% pro forma vs prior year; operating income $1.1M","Thyroid test volume grew 12% year-over-year to record levels; thyroid revenue $8.8M, up 22%","Cash collections $10.0M in Q3; days sales outstanding reduced 22%","Income from continuing operations $1.0M; adjusted EBITDA $1.3M","Company completed transition to thyroid-only diagnostics; additional debt principal payments made"],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":29504000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133561,"accession_number":"0001641172-25-022774","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q2 revenue down 23% to $9.2M; loss from continuing ops $0.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $9.2M (-23% YoY); loss from continuing ops $0.5M vs income $2.5M a year ago.","Thyroid test volume up 16% YoY; thyroid revenue $8.7M (+25% YoY) to record levels.","Gross margin 57% (65% ex one-time PancraGEN impact); adjusted EBITDA $0.4M vs $2.8M.","One-time charge $1.2M from PancraGEN reimbursement loss; company winding down test.","Preliminary July 2025 revenue $3.3M (+54% YoY); management sees Q3 improvement."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":20747000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150235,"accession_number":"0001641172-25-009273","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q1 revenue $11.5M (+13% YoY); guides FY2025 ~$38M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $11.5M (+13% YoY); income from continuing ops $1.8M vs $0.8M.","Thyroid revenue $8.0M (+19% YoY) to record; test volume up 16%.","Cash collections $11.3M (+10% YoY) to record; adjusted EBITDA $2.1M vs $1.2M.","Initiates FY2025 revenue guidance of approx. $38M despite PancraGEN loss after May 2.","Gross profit margin improved to 64% from 62%."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":11515000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150234,"accession_number":"0001641172-25-007944","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.","Workforce reduction announced; severance costs $0.5-0.6M in Q2 plus $0.2M in Q1 2025.","Restructuring to cut annual cost of revenue and OpEx by $12.5-14.5M, offsetting ~1/3 of revenue loss.","Plan substantially complete by end of Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169244,"accession_number":"0001493152-25-009384","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.","Restatement expected to reduce liabilities and increase net income; revenues and cash flows unchanged.","Non-reliance on financial statements for FY2023, Q1-Q3 2023 and Q1-Q3 2024.","Management will report a material weakness in internal controls over accrued royalty assessment.","Cumulative impact from 2015-2022 is $4.8M aggregate; no restatement for periods before 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169243,"accession_number":"0001493152-25-003797","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-01-27T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Interpace Biosciences: CMS delays Genetic Testing LCD to April 24, 2025; Company re-evaluates restructuring plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS directed Medicare contractors to delay implementation of LCD L39365 from Feb 23 to April 24, 2025.","Delay allows Trump administration to review clinical evidence for PancraGEN assay and assess patient impact.","Interpace will continue offering PancraGEN and re-evaluate its previously announced restructuring plan.","CEO Burnell stated the company is sustainable without PancraGEN but extension preserves jobs and patient access.","PancraGEN has been covered by Medicare for over 10 years, helped over 80,000 patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169242,"accession_number":"0001493152-25-003019","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-01-21T23:59:59+00:00","items":["1.01","2.03","2.05"],"status":"ready","headline":"Interpace restructures debt and cuts workforce after CMS drops PancraGEN coverage","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fourth Amendment: monthly $500k principal payments Feb-Jun 2025, interest-only Jul-Dec, final balance due Dec 31, 2025; 1% restructuring fee paid on Jan 17, 2025.","Board approved restructuring plan Jan 14, 2025 due to CMS ending PancraGEN coverage (announced Jan 9, 2025).","Workforce reduction; severance costs estimated $0.8M–$1.0M, primarily recorded in Q1 2025.","Expected annual cost savings of $12.5M–$14.5M, expected to offset approximately one-third of revenue loss from PancraGEN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169241,"accession_number":"0001493152-25-001699","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CMS final LCD denies coverage for Interpace's PancraGEN test; company to discontinue after Feb 7, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS issued final LCD L39365 establishing non-coverage for PancraGEN, a DNA-based test assessing pancreatic cyst cancer risk.","Interpace will stop accepting PancraGEN specimens after February 7, 2025; test primarily ordered for Medicare patients.","PancraGEN has helped over 80,000 patients since 2013; CEO calls decision inconsistent with advancing patient care.","Company plans restructuring but expects to remain profitable with ThyGeNEXT + ThyraMIR v2 thyroid tests.","Interpace will consider all remedies against CMS/Novitas regarding the non-coverage decision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186283,"accession_number":"0001493152-24-045132","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders ratify appointment of EisnerAmper as auditor for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Over 10.97M shares voted FOR ratification, 13,711 against, 2,680 abstained.","Ratification passed with overwhelming majority; no broker non-votes.","Only item voted on at 2024 annual meeting held November 12, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186282,"accession_number":"0001493152-24-043851","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Biosciences Q3 revenue $12.3M, record test volume, swings to profit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenue $12.3M, up 35% YoY ($9.1M); test volume up 26% to record levels.","Operating income $1.9M vs operating loss of $0.02M a year ago; adjusted EBITDA $2.1M vs $0.4M.","Income from continuing ops $1.4M vs loss of $0.5M; gross margin 61% up from 55%.","Cash collections $11.3M (+15% YoY); cash $2.1M after $6.6M debt paydown; 18th consecutive quarter of YoY volume growth.","Company interviewing equity research partners and investment bankers for capital raise and potential Nasdaq listing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":34610000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186281,"accession_number":"0001493152-24-041144","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","7.01","9.01"],"status":"ready","headline":"Interpace exchanges all Series B Preferred for Series C Preferred; first step toward Nasdaq uplisting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 47,000 Series B Preferred shares (28,000 Ampersand, 19,000 1315 Capital) exchanged for Series C at $1,000 stated value.","Series C converts at $2.02/share (date closing price), no liquidation preference, no director designation rights, limited protective provisions.","Series C automatically converts to common upon Nasdaq uplisting; company believes Series C qualifies as stockholders' equity under GAAP.","Amended investor rights agreement provides registration rights; prior support agreement with 1315 Capital terminated.","Exchange is first step toward Nasdaq uplisting; no cash received; additional listing requirements may need to be satisfied."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202905,"accession_number":"0001493152-24-030102","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q2 revenue $12.0M (+9% YoY); operating income $2.2M vs $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Test volume up 12% YoY to record levels; sixteenth consecutive quarter of YoY volume growth.","Operating income $2.2M vs $0.8M in prior-year quarter; income from continuing ops $2.1M vs $0.4M.","Adjusted EBITDA $2.3M vs $1.3M; cash collections $11.0M (+7% YoY).","Cash balance $2.0M at June 30, 2024, down from $5.1M due to $4.6M additional long-term debt paydown.","Gross profit margin stable at 62%; operating expenses down ~14% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":22314000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219103,"accession_number":"0001493152-24-018465","cik":1054102,"company_name":"INTERPACE BIOSCIENCES, INC.","ticker":"IDXG","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Interpace Q1 revenue $10.3M (+4% YoY); income from ops $0.6M; record test volume +10%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net revenue $10.3M, up 4% YoY from $9.8M; test volume up 10% to record levels.","Income from continuing ops $0.6M vs $0.4M prior year; operating income $0.9M vs $0.7M.","Adjusted EBITDA $1.0M vs $1.2M prior year; gross margin 59% vs 61%.","Cash collections $10.2M; cash balance $2.8M at Mar 31, 2024, down from $5.6M due to $3.1M debt paydown.","Fifteenth consecutive quarter of YoY volume growth; CEO cites adoption of ThyGeNEXT, ThyraMIRv2, PancraGEN."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":10273000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49861627.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}